Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Velcade (bortezomib) with cisplatin as first-line treatment of malignant mesothelioma
2006-000009-51Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2006
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and cisplatin in pleural mesothelioma, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival rate at 18 weeks. Started Nov 2006; status: completed.
02
Drugs
bortezomibcisplatin
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2006-000009-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000009-51.